Gilead Sciences, Inc. (GILD) Upgraded to Buy at HSBC

Market Context

Gilead Sciences, Inc. operates in the Healthcare sector. The stock currently trades at $129.61 with a market capitalization of $152.9B. The stock has gained 5.7% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. HSBC's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Gilead Sciences, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 06, 2026	Cantor Fitzgerald	Overweight	N/A
Jul 06, 2026	HSBC	Buy	N/A
Jun 16, 2026	Cantor Fitzgerald	Overweight	N/A
May 20, 2026	Maxim Group	Buy	N/A
May 08, 2026	RBC Capital	Sector Perform	N/A

Related Tools: Analyst Ratings Dashboard | View GILD Stock Page